Efficacy and safety of once-daily glycopyrronium in predominantly Chinese patients with moderate-to-severe chronic obstructive pulmonary disease: the GLOW7 study

BACKGROUND: Glycopyrronium is a once-daily (od) long-acting muscarinic antagonist for the maintenance treatment of chronic obstructive pulmonary disease (COPD). The GLOW7 study evaluated the efficacy and safety of od glycopyrronium 50 μg in predominantly Chinese patients with moderate-to-severe COPD...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Int J Chron Obstruct Pulmon Dis
Hlavní autoři: Wang, Chen, Sun, Tieying, Huang, Yijiang, Humphries, Michael, Bai, Lingyan, Li, Lilly, Wang, Qian, Kho, Pearl, Firth, Roz, D’Andrea, Peter
Médium: Artigo
Jazyk:Inglês
Vydáno: Dove Medical Press 2015
Témata:
Original Research
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4293291/
https://ncbi.nlm.nih.gov/pubmed/25609940
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/COPD.S72650
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky